Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study.

Journal: Clinical kidney journal
Published Date: Dec 16, 2021

Abstract

BACKGROUND: Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and observational study aiming to provide insights into undiagnosed stage 3 CKD in a large population.

Authors

  • Pamela Kushner
    University of California, Irvine, CA, USA.
  • Emily Peach
    Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Eric Wittbrodt
    Cardiovascular, Renal and Metabolism Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
  • Salvatore Barone
    Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
  • Hungta Chen
    Medical/Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
  • Juan Jose Garcia Sanchez
    Global Market Access and Pricing, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Krister Järbrink
    Cardiovascular, Renal and Metabolism Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Mölndal, Sweden.
  • Matthew Arnold
    Faculty of Health and Medical Sciences, Adelaide Medical School, University of Adelaide, Adelaide, SA 5000 Australia.
  • Navdeep Tangri
    Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals